GRI Bio, Inc. (GRI)
Nasdaq: GRI · Pharmaceutical Preparations · La Jolla, CA · filing with the SEC since 2020
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Jan 30, 2026 | Mar 14, 2025 | Mar 28, 2024 | Feb 24, 2023 | Feb 14, 2022 | Mar 29, 2021 |
| Revenue | · | · | · | · | 0 | 100 |
| Research and development | 6,819 | 3,768 | 3,232 | 242r | 5,187 | 3,707 |
| General and administrative | 5,158 | 4,467 | 8,155 | 1,997r | 4,072 | 1,181 |
| Total operating expenses | 11,977 | 8,235 | 11,387 | 2,239r | 9,259 | 4,888 |
| Operating income | -11,977 | -8,235 | -11,387 | -2,239r | -9,259 | -4,788 |
| Interest income (expense), net | 21 | 25 | -2,082 | -653r | -16 | -34 |
| Other income (expense), net | · | 0 | 250 | 0 | 61 | 0 |
| Income tax expense | 3 | 2 | · | · | · | · |
| Net income | -11,956 | -8,207 | -13,037 | -3,217r | -9,303 | -4,822 |
| Net income to common shareholders | -11,956 | -10,118 | -13,037 | · | · | · |
| Earnings per share, basic | -121.80 | -1,545.55r | -140,506.52rb | -124,350.80rb | -7,077.28b | -5,332.88b |
| Earnings per share, diluted | -121.80 | -1,545.55r | -140,506.52rb | -124,350.80rb | -7,077.28b | -5,332.88b |
| Weighted average shares, basic | 98,162 | 6,547r | 93rb | 26rb | 1,312b | 904b |
| Weighted average shares, diluted | 98,162 | 6,547r | 93rb | 26rb | 1,312b | 904b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-28 reverse split of Jan 2026.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest income (expense), net interest earned less interest paid, outside the business
us-gaap:InterestIncomeExpenseNonoperatingNetOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding